Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

533 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A newly established monoclonal antibody against ERCC1 detects major isoforms of ERCC1 in gastric cancer.
Oishi T, Sasaki Y, Tong Y, Chen L, Onodera T, Iwasa S, Udo E, Furusato B, Fujimori H, Imamichi S, Honda T, Bessho T, Fukuoka J, Ashizawa K, Yanagihara K, Nakao K, Yamada Y, Hiraoka N, Masutani M. Oishi T, et al. Among authors: hiraoka n. Glob Health Med. 2021 Aug 31;3(4):226-235. doi: 10.35772/ghm.2021.01001. Glob Health Med. 2021. PMID: 34532603 Free PMC article.
Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.
Tada K, Kitano S, Shoji H, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Yamada Y, Katayama N, Boku N, Heike Y, Hamaguchi T. Tada K, et al. Among authors: hiraoka n. Cancer Immunol Res. 2016 Jul;4(7):592-9. doi: 10.1158/2326-6066.CIR-15-0298. Epub 2016 Apr 28. Cancer Immunol Res. 2016. PMID: 27197061
The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy.
Shoji H, Tada K, Kitano S, Nishimura T, Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, Takashima A, Kato K, Boku N, Honda K, Yamada T, Heike Y, Hamaguchi T. Shoji H, et al. Among authors: hiraoka n. Oncotarget. 2017 May 30;8(56):95083-95094. doi: 10.18632/oncotarget.18297. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221113 Free PMC article.
Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.
Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T. Sunami K, et al. Among authors: hiraoka n. Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2. Cancer Sci. 2019. PMID: 30742731 Free PMC article.
Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma.
Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Asahina D, Ushigome M, Hiraoka N, Nagino M, Kondo T. Morofuji N, et al. Among authors: hiraoka n. J Proteomics. 2012 Feb 16;75(5):1577-89. doi: 10.1016/j.jprot.2011.11.030. Epub 2011 Dec 6. J Proteomics. 2012. PMID: 22155129 Clinical Trial.
533 results